INVION ORD
Korean partner backs Invion’s INV043 ahead of Australia first-in-human trial
Invion (ASX: IVX) partners with Hanlim on a $2m non-clinical program to advance INV043 for oesophageal cancer toward first-in-human trials, backed by KDDF grant.
Invion advances skin cancer treatment with positive safety data for INV043 in Phase I/II trial
Invion (ASX: IVX) has reported no adverse events from the application and use of its lead drug candidate INV043 on the first six patients of a Phase I/II non-melanoma skin cancer (NMSC) trial in Queensland. Data from a safety review committee (SRC) suggested that treatment with the novel photosensitiser was well-tolerated and feedback from clinicians […]
Weekly wrap: shares take a breather as Wall Street finds caution
Australia’s share market took a breather on Friday as Wall Street turned cautious about whether the Federal Reserve will continue to cut interest rates this month. By the close of trade the ASX 200 had dropped 0.6% or 54 points to 8420.9 points with only one of the 11 sectors closing up. The fall meant […]
Invion commences dosing in INV043 trial to treat non-melanoma skin cancer
Clinical-stage life sciences company Invion (ASX: IVX) has dosed the first patient in its Phase I/II non-melanoma skin cancer (NMSC) trial using active pharmaceutical ingredient and lead candidate INV043. The trial will aim to evaluate the safety and efficacy of the topically applied INV043, a novel photosensitiser developed in Australia for use in photodynamic therapy […]